pharmaceuticals

pharmaceuticals Articles

Portola Pharmaceuticals made waves early on Thursday morning with less than favorable top-line results.
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Akorn reported its preliminary 2015 financial results before the markets opened on Tuesday and issued guidance for the 2016 full year.
Celator Pharmaceuticals reported its fourth-quarter financial results before the markets opened on Monday.
Advaxis made waves in the markets on Monday following the release of positive data from its most recent study.
BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.
Releasing preliminary results may have been ill-advised to release, as the impact was absolutely catastrophic to Valeant Pharmaceuticals stock.
Over the past week, Celator Pharmaceuticals and a few other biotech companies made impressive runs.
Pfizer announced the results from its first two pivotal Phase 3 studies from the Oral Clinical Trials for tofacitinib in ulcerative colitis program at the 11th Congress of European Crohn's and...
Eagle Pharmaceuticals shares were in free fall early Friday after it received a Complete Response Letter from the FDA for its Kangio.
Vitae Pharmaceuticals watched its shares absolutely take off on Thursday morning following the release of positive results from its mid-stage clinical trial.
Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
24/7 Wall St. has collected a few more U.S. Food and Drug Administration (FDA) decisions coming up in March.